Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cyberonics (cybx) epilepsy therapy recommonded -- Ignore unavailable to you. Want to Upgrade?

To: Valentin who wrote (243)	4/7/1998 7:05:00 PM
From: fred woodall	Respond to of 471

CYBX 29.875 (-.312) Cyberonics Inc. said Tuesday it received approval from the Food and Drug Administration to incorporate two improvements into its manufacturing processes for its NeuroCybernetic Prosthesis system, an implantable vagus-nerve stimulator. The NeuroCybernetic Prosthesis system sends preprogrammed electrical stimulation to the vagus nerve through a small generator, acting as a pacemaker for the brain. Cyberonics, a medical-device company (CYBX), said the improvements combine changes to the system's epoxy-header pouring and curing process and allow the company to perform its laser making process internally. The improvements are EXPECTED TO SHORTEN ITS MANUFACTURING CYCLE BY ABOUT A WEEK.